Aspen Pharmacare’s efforts to develop and manufacture medicines and vaccines for the African continent received a boost with the securing of a R9.9bn loan from World Bank’s International Finance Corporation (IFC), reported Business Day (3 September 2024).
“Aspen CEO Stephen Saad revealed that the company had been approached to produce mpox vaccines. However, he emphasised that Aspen would only proceed if two essential conditions were met: Someone else must cover the tech transfer costs, and we need a guaranteed assurance of volumes.”
Aspen’s market capitalisation now stands at R91.93bn.